Blog

For over 20 years, the US government and the FDA have worked hard to stop opioid abuse and misuse. In the past, the FDA mostly used reactive tools, such as warning labels and doctor education programs, to control how these strong painkillers were handed out. Recently, the FDA took a giant leap forward by releasing five … Read more

Ensuring the safety of food products crossing United States borders is an intensive, risk-based administrative mandate. Regulatory compliance professionals know that the Foreign Supplier Verification Program (FSVP) regulations, enforced under 21 CFR part 1, subpart L, demand absolute precision. Unfortunately, a recent string of warning letters issued by the FDA reveals a widespread, systemic failure among food … Read more

The successful commercialization of orally administered therapeutic entities hinges on a meticulous understanding of systemic exposure variability. When developing novel small molecules or modified-release formulations, clinical pharmacologists must strictly characterize the impact of physiological states on drug absorption. The intersection of gastrointestinal physiology and xenobiotic metabolism presents a complex regulatory hurdle for sponsors seeking marketing authorization. Failing … Read more

The FDA’s Digital Health Center of Excellence recently operationalized the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program to address the dichotomy between stringent premarket review timelines and iterative software life cycles. Launched in tandem with the Center for Medicare and Medicaid Innovation’s (CMMI) ACCESS model, TEMPO establishes an unprecedented mechanism for early-stage real-world deployment. Understanding the mechanics of this pilot … Read more

For decades, pregnant women have remained one of the most systematically excluded populations in pre-approval clinical development programs. As a result, many therapeutics enter the market with limited or no human pregnancy safety data despite anticipated real-world exposure shortly after commercialization. FDA’s May 2026 guidance, Postapproval Pregnancy Safety Studies, represents a significant evolution in regulatory expectations for pregnancy pharmacovigilance and real-world evidence generation. … Read more

The integration of generative AI into clinical workflows has triggered a “shadow IT” movement, where practitioners leverage unvetted Large Language Models (LLMs) to manage increasing administrative burdens without official institutional oversight. While platforms like OpenEvidence offer high-velocity access to peer-reviewed literature, the lack of transparency in these non-deterministic systems creates a significant “black box” liability. Regulatory professionals … Read more

The U.S. Food and Drug Administration recently unveiled a provocative shift in its oversight strategy by launching one-day inspectional assessments for manufacturing facilities. This program moves away from the multi-day, comprehensive deep dives that have long been the gold standard of regulatory compliance. By focusing on high-priority, risk-based indicators, the agency aims to broaden its … Read more

The Food and Drug Administration is no longer just a regulator of medicine; it is becoming a powerhouse of data science. For decades, the agency struggled under the weight of massive application backlogs and fragmented legacy systems. Today, the FDA is undergoing a digital metamorphosis, integrating sophisticated AI tools like “Elsa” to streamline how we ensure public … Read more

In the complex landscape of pediatric nutrition, the stability of the infant formula market remains a paramount concern for both federal regulators and industry stakeholders. Recent years have demonstrated that even minor supply chain disruptions can lead to significant public health crises and socioeconomic volatility. To fortify consumer confidence and ensure product integrity, the FDA has prioritized rigorous oversight through … Read more